Chapter 2 Summary and Highlights
- Market Outlook
- This Report Highlights
Chapter 3 Market Overview and Definitions
- Overview
- Acute Myeloid Leukemia
- The Global Regulatory Structure for Aml
- Pricing and Reimbursement for Aml
- Therapies/Drugs to Treat Aml
- Flt3 Inhibitors
- Idh Inhibitors
- Apoptosis Stimulants
- DNA Methylation Inhibitors
- DNA Intercalators
- Angiogenesis Inhibitors
- DNA Synthesis Inhibitors
Chapter 4 Market Dynamics
- Market Drivers
- Growing Elderly Population
- Increasing Incidence and Prevalence
- Advancements in Molecular Diagnostics
- Minimal Residual Disease (Mrd) Monitoring
- Gene Expression Profiling
- Fusion Gene Detection
- Liquid Biopsies
- R&D
- Regulatory Environment
- Personalized Medicine
- Collaborative Efforts
- Patient Advocacy and Awareness
- Market Opportunity
- Strategic Initiative
- Market Restraints
- High Costs
- Limited Treatment Options
- Treatment-Related Toxicity and Adverse Effects
- Regulatory and Reimbursement Challenges
Chapter 5 Impact of Covid-19
- Introduction
- Covid-19 Impact on Aml Treatments
- Chapter 6 Market Breakdown by Region
- Market Overview and Discussion
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Market Breakdown by Treatment Type
- Market Overview and Discussion
- Targeted Therapy
- Anthracycline Drugs
- Other Chemotherapies
- Targeted Therapy
- Anthracycline Drugs
- Other Chemotherapies
Chapter 8 Market Breakdown by Route of Administration
- Market Overview and Discussion
- Intravenous (Iv) Administration
- Oral Administration
- Intravenous (Iv) Administration
Chapter 9 Market Breakdown by Product
- Flt3 Inhibitors
- Apoptosis Stimulants
- Angiogenesis Inhibitors
- DNA Methylation Inhibitors
- DNA Synthesis Inhibitors
- DNA Intercalators
Chapter 10 Esg Development
- Introduction
- Environment
- Governance
Chapter 11 Emerging Trends and Technologies
Chapter 12 Competitive Landscape
- Overview
- Industry Scenario
- Company Shares
Chapter 13 Patent Analysis
- Patent Analysis by Manufacturer
Chapter 14 Pipeline Analysis
Chapter 15 M&A and Venture Funding Outlook
Chapter 16 Company Profiles
- Abbvie
- Amgen Inc.
- Astellas Pharma Inc.
- Bayer AG
- Biogen
- Bristol Myers Squibb
- Daiichi Sankyo Co. Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis
- Pfizer Inc.
- Sanofi
- Servier Laboratories
- Teva Pharmaceutical Industries Ltd.
List of Tables
Summary Table: Global Market for AML Treatments, by Drug Type, Through 2028
Table 1: Global Population, Aged 60+, 2010-2050
Table 2: North America, New Patents, 2023
Table 3: AML Treatment: Targeted Therapy Drugs
Table 4: AML Treatment Cost, by Country
Table 5: AML Treatment-related Toxicities and Adverse Effects
Table 6: Global COVID-19 Cases, 2023
Table 7: Global Market for AML Treatments, by Region, Through 2028
Table 8: North American Market for AML Treatments, by Country, Through 2028
Table 9: European Market for AML Treatments, by Country, Through 2028
Table 10: Asia-Pacific Market for AML Treatments, by Country, Through 2028
Table 11: RoW Market for AML Treatments, Through 2028
Table 12: Global AML, by Treatment Type, Targeted Therapy
Table 13: Global Market for AML Treatments, by Targeted Therapy, Through 2028
Table 14: Global Market for AML Treatments, by Anthracycline Drugs, Through 2028
Table 15: Global Market for AML Treatments, by Other Chemotherapies, Through 2028
Table 16: Global Market for AML Treatments, by IV Administration, Through 2028
Table 17: Global AML IV Treatment
Table 18: Global AML IV Treatment Cycle
Table 19: Global Market for AML Treatments, by Oral Route Administration, Through 2028
Table 20: Global AML, Oral Treatment
Table 21: Global Market for AML Treatments, by Product, Through 2028
Table 22: Global Market for AML Treatments, FLT3 Inhibitors, Through 2028
Table 23: Global Market for AML Treatments, Apoptosis Stimulants, Through 2028
Table 24: Global Market for AML Treatments, IDH Inhibitors, Through 2028
Table 25: Global Market for AML Treatments, Angiogenesis Inhibitors, Through 2028
Table 26: Global Market for AML Treatments, DNA Methylation Inhibitors, Through 2028
Table 27: Global Market for AML Treatments, DNA Synthesis Inhibitors, Through 2028
Table 28: Global Market for AML Treatments, DNA Intercalators, Through 2028
Table 29: ESG Framework for the Global Pharmaceutical Industry
Table 30: Social Framework, Global Pharmaceutical Industry
Table 31: Top Pharma Companies, ESG Ratings
Table 32: Global Market for AML Treatments, New Technologies
Table 33: Global AML Treatments, by Company Market Share, 2022
Table 34: Global AML Treatments, by Product Share, 2022
Table 35: Global AML Treatments, by Product Sales, 2022
Table 36: Global AML Treatments, Company Information
Table 37: Global AML Treatments, Key Financials, 2022
Table 38: Patents on AML Drugs, 2018-Present
Table 39: Selected Manufacturer Patents on AML Drugs, 2018-Present
Table 40: Patents on FLT3 Inhibitors, 2018-Present
Table 41: Selected Manufacturer Patents on FLT3 Inhibitors, 2018-Present
Table 42: Patents on Apoptosis Stimulants, 2018-Present
Table 43: Selected Manufacturer Patents on Apoptosis Stimulants, 2018-Present
Table 44: Patents on IDH Inhibitors, 2018-Present
Table 45: Selected Manufacturer Patents on IDH Inhibitors, 2018-Present
Table 46: Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 47: Selected Manufacturer Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 48: Patents on DNA Methylation Inhibitor, 2018-Present
Table 49: Selected Manufacturer Patents on DNA Methylation Inhibitor, 2018-Present
Table 50: Selected Apoptosis Stimulants in Clinical Trials, 2023
Table 51: Selected IDH Inhibitors in Clinical Trials, 2023
Table 52: Selected IDH Inhibitors in Clinical Trials, 2023
Table 53: Selected DNA Methylation Inhibitors in Clinical Trials, 2023.
Table 54: Selected FLT3 Inhibitors in Clinical Trials, 2023
Table 55: Selected DNA Synthesis Inhibitors in Clinical Trials, 2023
Table 56: Global AML Treatment Market: Mergers and Acquisitions, 2019-2022
Table 57: AbbVie: Product Information
Table 58: AbbVie: Revenue, 2020-2022
Table 59: AbbVie: Recent Key Developments
Table 60: Amgen: Revenue, 2020-2022
Table 61: Amgen: Key Developments, 2021 and 2022
Table 62: Astellas Pharma: Revenue, 2020-2022
Table 63: Astellas Pharma: Recent Key Developments
Table 64: Bayer AG: Marketed Products
Table 65: Bayer AG: Annual Revenue, 2020-2022
Table 66: Bayer AG: Key Developments, 2022 and 2023
Table 67: Biogen: Annual Revenue, 2020-2022
Table 68: Biogen: Key Developments, 2018-2023
Table 69: Bristol-Myers Squibb: Product Information
Table 70: Bristol-Myers Squibb: Revenue, 2020-2022
Table 71: Bristol-Myers Squibb: Key Developments, 2020 and 2021
Table 72: Daiichi Sankyo: Product Information
Table 73: Daiichi Sankyo: Annual Revenue, 2020-2022
Table 74: Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75: Gilead Sciences: Annual Revenue, 2020-2022
Table 76: Gilead Sciences: Key Developments, 2022 and 2023
Table 77: GlaxoSmithKline PLC: Product Segment
Table 78: GlaxoSmithKline PLC: Annual Revenue, 2020-2022
Table 79: GlaxoSmithKline PLC: Recent Developments, 2022
Table 80: Merck & Co. Inc.: Business Segment
Table 81: Merck & Co. Inc.: Annual Revenue, 2020-2022
Table 82: Merck & Co. Inc.: Key Developments, 2022
Table 83: Novartis: Product Information
Table 84: Novartis: Revenue, 2020-2022
Table 85: Novartis: Key Developments
Table 86: Pfizer Inc.: Product Segments
Table 87: Pfizer Inc.: Annual Revenue, 2020-2022
Table 88: Pfizer Inc.: Top Brands, 2022
Table 89: Pfizer Inc.: Key Developments, 2019-2023
Table 90: Sanofi: Business Segment
Table 91: Sanofi: Annual Revenue, 2020-2022
Table 92: Sanofi: Key Developments, 2021-2023
Table 93: Servier: Product Information
Table 94: Servier: Annual Revenue, 2020-2022
Table 95: Servier: Key Developments, 2022 and 2023
Table 96: Teva: Financials, 2020-2022
Table 97: Teva: Key Developments, 2021-2023
Table 98: Acronyms Used in This Report
List of Figures
Summary Figure A: Global Market for AML Treatments, by Drug Type, 2020-2028
Summary Figure B: Global Market Shares of AML Treatments, by Drug Type, 2022
Figure 1: Global Market Shares of AML Treatments, by Region, 2022
Figure 2: North American Market Shares of AML Treatments, by Country, 2022
Figure 3: European Market Shares of AML Treatments, by Country, 2022
Figure 4: Asia-Pacific Market Shares of AML Treatments, by Country, 2022
Figure 5: Global AML Treatment Market Shares, by Drug Type, 2022
Figure 6: Global Market Shares of AML Treatments, by Route of Administration, 2022
Figure 7: Global Market Shares of AML Treatments, by Oral Route Administration, 2022
Figure 8: Global Market Shares of AML Treatments, by Product, Through 2028
Figure 9: Global Electricity from Renewable Sources, 2017-2021
Figure 10: Global Recycled Waste, 2017-2021
Figure 11: Global CO<sub>2</sub> Emissions, 2017-2021
Figure 12: Global AML Treatments, by Company Market Share, 2022
Figure 13: Global AML Treatments, by Product Sales, 2022
Figure 14: AbbVie: Market Share, by Country, 2022
Figure 15: Bristol-Myers Squibb: Revenue Share, by Country, 2022
Figure 16: Daiichi Sankyo: Market Share, by Region/Country, 2022
Figure 17: Gilead Sciences: Revenue, by Product, 2022
Figure 18: GlaxoSmithKline PLC: Annual Revenue, by Segment, 2020-2022
Figure 19: Merck & Co. Inc.: Annual Revenue, by Segment, 2020-2022
Figure 20: Novartis Innovative Medicine: Market Share, by Region/Country, 2022
Figure 21: Novartis Sandoz: Market Share, by Region/Country, 2022
Figure 22: Sanofi: Revenue, by Region/Country, 2022
Figure 23: Sanofi: Revenue, by Segment, 2022
Figure 24: Teva: Market Share, by Region, 2022
